A caller has been reading about GLP-1 medications and peptide protocols for a month. She has watched the videos, read the forums, and decided she wants to try. When she finally phones your longevity clinic, her first real question is not what it costs. It is quieter and more decisive than that: do I even qualify, and can I do this without coming in for a visit. How your front desk fields that question determines whether a person who has already talked herself into starting starts with you, or with whoever answers the phone more usefully next.

This is the eligibility caller. She is at the top of the buying curve, she is easy to lose, and she is lost most often not to a competitor with better medicine but to a front desk that could not tell her anything and did not book her anything.

What eligibility actually looks like in 2026

The desk cannot and must not diagnose, but it should know the shape of the eligibility picture well enough to route intelligently.

• The baseline thresholds. FDA-approved GLP-1 therapy for chronic weight management generally starts at a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Most telehealth-based programs follow the same frame.

• The qualifying conditions. Recognized comorbidities commonly include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, and cardiovascular disease, with some programs also weighing fatty liver disease, osteoarthritis, and polycystic ovary syndrome.

• The hard stops. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication. This is a clinician judgment, not a desk judgment, but it is the kind of flag a good intake surfaces early rather than at the pharmacy.

• The telehealth reality. Licensed clinicians can evaluate and prescribe remotely after an appropriate clinical assessment. On the supply side, branded GLP-1 prescribing is standard, and patient-specific 503A compounding remains available where a documented clinical need exists, after the FDA declared the semaglutide shortage resolved on February 21, 2025.

Why the eligibility question is a booking, not an FAQ

The caller asking whether she qualifies is not asking for a diagnosis. She is asking for permission to hope this will work for her, and for a path to find out. When the desk answers with a version of you will have to ask the provider and offers nothing else, it strands the most motivated caller of the day between wanting to start and knowing how. She does not wait. She calls the next name on her list.

Part of the difficulty is that these callers often cannot name what they want precisely, which is the same intake-translation problem covered in the caller who cannot name the program she is asking for. And the value of getting the first response right is compounded by what happens after month three, the retention cliff detailed in the GLP-1 clinic retention cliff: a caller lost at hello never reaches the point where the program actually pays off.

What a compliant intake does with "do I qualify"

A front desk built for this vertical treats the eligibility question as a routing task with four moves, none of which cross into clinical advice.

• Capture the signals, not a diagnosis. The intake can note the general thresholds a clinician will review and gather the basics that let the consultation start informed, without telling the caller whether she is approved.

• Set the telehealth expectation. Tell her plainly that eligibility is decided in a clinical assessment she can do remotely, so she knows the next step is real and near, not a hurdle.

• Disclose honestly. If an automated assistant is taking the call, it should identify itself as the practice assistant and offer a person on request. In a program a caller will be on for months, the relationship starts with that honesty.

• Book the consultation and connect it to the whole program. A GLP-1 or peptide start is the front door to a longer arc of care, the cross-service cadence described in how a biohacking clinic sequences services over time, and the reactivation economics in the GLP-1 compounding cliff.

The math most clinics have not run

Illustrative model - not a client result or guarantee. A longevity program is not a single transaction. A GLP-1 or peptide patient who starts and stays represents months of recurring program value, so the cost of a mishandled eligibility call is not one lost sale, it is one lost program. If a clinic takes even a dozen eligibility calls a week and loses a third of them to a vague answer at the desk, the annual figure attached to those four words is not small. The direction is the whole point: the eligibility caller is the highest-intent person who will phone all week, and she is the one a thin front desk is most likely to lose. Sizing that leak for a specific practice is what the Intake Leak Audit is for.

References

• Telehealth GLP-1 eligibility guides (TeleHealthAlly, Middleway Nutrition, TrimRX), 2026: BMI thresholds of 30, or 27 with a comorbidity, and recognized qualifying conditions.

• FDA labeling on GLP-1 contraindications (medullary thyroid carcinoma, MEN type 2); telehealth prescribing after clinical assessment.

• MedSpa Standards and industry coverage, 2026: branded prescribing and 503A patient-specific compounding after the FDA declared the semaglutide shortage resolved on February 21, 2025.

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline is leaking revenue. We quantify this for your practice in a 30-minute Intake Leak Audit.

• Request an Intake Leak Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664.